ArticleBiomacromolecules2014
In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice.
Article in Biomacromolecules, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- New Strategies in Comprehensive Melanoma Treatment: Applications, Potential, and Challenges of Hydrogels.International journal of nanomedicine · 2025Pooled it
- Smart drug delivery systems for immunotherapeutic agents: focus on biological/biogenic platform-based intelligent delivery in cancer immunotherapy.Drug delivery and translational research · 2026Review
- Localized Hydrogel-Based Therapeutics: A Strategic Approach to Mitigating Postoperative Recurrence in Breast Cancer.Polymers · 2026Review
- Hydrogels in the Immune Context: In Vivo Applications for Modulating Immune Responses in Cancer Therapy.Gels (Basel, Switzerland) · 2025Review
- Hydrogels as advanced drug delivery platforms for cancer immunotherapy: promising innovations and future outlook.Journal of nanobiotechnology · 2025Review
- A review of synergistic strategies in cancer therapy: resveratrol-loaded hydrogels for targeted and multimodal treatment.Discover oncology · 2025Review
- Immune Cell Homing Hydrogels for Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.Experimental hematology & oncology · 2024Review
- Hydrogel systems for spatiotemporal controlled delivery of immunomodulators: engineering the tumor immune microenvironment for enhanced cancer immunotherapy.Frontiers in cell and developmental biology · 2024Review
- Bio-adhesive Macroporous Hydrogels for In Situ Recruitment and Modulation of Dendritic Cells.Cellular and molecular bioengineering · 2023Article
- Emerging phagocytosis checkpoints in cancer immunotherapy.Signal transduction and targeted therapy · 2023Review
- Self-Healing Injectable Hydrogels for Tissue Regeneration.Chemical reviews · 2023Review
- Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment.Pharmaceutics · 2022Article
- Current and Future Prospective of Injectable Hydrogels-Design Challenges and Limitations.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Regulation of biomaterial implantation-induced fibrin deposition to immunological functions of dendritic cells.Materials today. Bio · 2022Article
- Activation of cancer immunotherapy by nanomedicine.Frontiers in pharmacology · 2022Review
- Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.Biomaterials · 2022Review
- In Situ Hydrogels for Effective Treatment of Cancer: Strategies and Polymers Used.Recent advances in drug delivery and formulation · 2022Article
- Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.Nature communications · 2021Article
- Injectable Hydrogels for Sustained Codelivery of Subunit Vaccines Enhance Humoral Immunity.ACS central science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Attempts to develop cell-based cancer vaccines have shown limited efficacy, partly because transplanted dendritic cells (DCs) do not survive long enough to reach the lymph nodes. The development of biomaterials capable of modulating DCs in situ to enhance antigen uptake and presentation has emerged as a novel method toward developing more efficient cancer vaccines. Here, we propose a two-step hybrid strategy to produce a more robust cell-based cancer vaccine in situ. First, a significant number of DCs are recruited to an injectable thermosensitive mPEG-PLGA hydrogel through sustained release of chemoattractants, in particular, granulocyte-macrophage colony-stimulating factor (GM-CSF). Then, these resident DCs can be loaded with cancer antigens through the use of viral or nonviral vectors. We demonstrate that GM-CSF-releasing mPEG-PLGA hydrogels successfully recruit and house DCs and macrophages, allowing the subsequent introduction of antigens by vectors to activate the resident cells, thus, initiating antigen presentation and triggering immune response. Moreover, this two-step hybrid strategy generates a high level of tumor-specific immunity, as demonstrated in both prophylactic and therapeutic models of murine melanoma. This injectable thermosensitive hydrogel shows great promise as an adjuvant for cancer vaccines, potentially providing a new approach for cell therapies through in situ modulation of cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.